Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer | Citedby Results | Oncology Research and Treatment | Karger Publishers

Skip to Main Content

Skip Nav Destination

Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer

Oncol Res Treat (2020) 43 (4): 153–159.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review

Zixuan He
Xianqin Huang
Dingyi Chen
Guoan Wang
Yuezhen Zhu
Huangqianyu Li
Sheng Han
Luwen Shi
Xiaodong Guan

BMJ Global Health (2023) 8 (11): e012780.

The anti‐adhesive effect of anti‐VEGF agents in experimental models: A systematic review

Dimitrios Giannis
Georgios Geropoulos
Ioannis A. Ziogas
Jordan Gitlin
Alisha Oropallo

Wound Repair and Regeneration (2021) 29 (1): 168.

Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review

Parsa Erfani
Kayleigh Bhangdia
Catherine Stauber
Jean Claude Mugunga
Lydia E. Pace
Temidayo Fadelu

The Oncologist (2021) 26 (8): e1406.

Bevacizumab plus paclitaxel not cost effective for HER2− MBC

PharmacoEconomics & Outcomes News (2020) 850 (1): 5.